LDL-C: what your result means.

LDL cholesterol (LDL-C) is the cholesterol carried in low-density lipoprotein particles, the primary vehicle delivering cholesterol into artery walls. It is the most-studied causal risk factor in all of cardiovascular medicine.

Why LDL-C matters

The causal case for LDL is closed: genetic studies, hundreds of thousands of trial participants and consistent dose-response effects led the European Atherosclerosis Society to formally conclude that LDL causes atherosclerotic cardiovascular disease. Cumulative lifetime exposure is what matters, which makes knowing your number early far more valuable than knowing it late.

Associated risks when out of range: Primary driver of atherosclerotic cardiovascular disease. Cumulative lifetime exposure determines plaque burden. Synergistic risk amplification with inflammation (hs-CRP) and Lp(a).

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets LDL-C, from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• EAS causality consensus (Ference et al. European Heart Journal 2017): reviewing over 200 studies with more than 2 million participants, the European Atherosclerosis Society formally concluded LDL causes atherosclerotic cardiovascular disease, with risk driven by both magnitude and duration of exposure.
• Cholesterol Treatment Trialists' meta-analysis (The Lancet 2010): across 26 randomised trials and ~170,000 participants, every 1 mmol/L reduction in LDL-C cut major vascular events by ~22%, proportionally, regardless of starting level.
• 4S trial (The Lancet 1994): the landmark trial that changed practice: lowering LDL with simvastatin reduced total mortality by 30% in patients with coronary disease, proof that lowering LDL saves lives, not just numbers.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets LDL-C against published clinical authority standards, never arbitrary "optimal" ranges. Measured in mmol/L:

Band	Range (mmol/L)
Optimal	<2.6 mmol/L
Borderline	2.6–3.5 mmol/L
High	3.6–4.5 mmol/L
Very high	>4.5 mmol/L

Clinical interpretation

• ApoB is a superior measure of atherogenic particle count. LDL-C can underestimate risk when particles are small and dense.
• Calculated LDL (Friedewald) is inaccurate when TG > 4.5 mmol/L; use direct LDL or ApoB.
• IMPORTANT: LDL-C <2.6 mmol/L is a reasonable preventive target for moderate-risk adults, but formal LDL-C treatment goals in ESC/EAS guidelines are tied to overall cardiovascular risk category (very high risk: <1.4, high risk: <1.8, moderate risk: <2.6), not a universal band. This distinction matters for clinician-facing decision support.
• In people with high triglycerides, diabetes, obesity, metabolic syndrome, or very low LDL-C, ApoB is the preferred primary or alternative risk marker (ESC/EAS 2019).

What improves it: the evidence-based levers

• Diet quality
• Soluble fibre
• Discuss medication if high-risk

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How LDL-C testing works at HodieLabs

LDL-C is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies (EAS Consensus Panel). Eur Heart J. 2017;38:2459–2472.
2. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (4S). Lancet. 1994;344:1383–1389.
4. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41:111–188.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.